China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and ...

Israel-based Teva Pharmaceutical Industries today announced that the US Food and Drug Administration (FDA) has accepted, and ...

Recombinant Dna Technology Market Set To Witness Significant Growth By 2024-2031: Sanofi , Pfizer, Inc., Amgen, Inc. Recombinant Dna technology market is expected to reach USD 327.63 Bn by 2031, ...

AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

IMTOZ trial findings and subsequent approval of Isa-VRd regimen for transplant-ineligible myeloma suggested the combo as a ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €100.00.

AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the National Medical Products Administration in China has ...

Regeneron (NASDAQ:REGN) and Sanofi (NASDAQ:SNY) announced Friday that the U.S. FDA approved a label expansion for its asthma ...

Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...

which has been cleared for a chronic lung disorder in the US and was developed with drugmaker Sanofi — offsetting any erosion ...